Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
Plus Therapeutics
Modality
radiopharmaceutical
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
40Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05460507CT.gov Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment | — | Recruiting | — | — | — |
NCT01906385CT.gov Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | — | Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
73High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Glioma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Rhenium Liposome Treatment (this asset) | Plus Therapeutics | P1/2 | CCC · 48 |
| Olutasidenib | Rigel Pharmaceuticals | P4 | BBB |
| Irinotecan | Kailin Yang, MD, PhD | P3 | B |
| Dianhydrogalactitol | Kintara Therapeutics, Inc. | P2 | B |
| Cyclophosphamide | Essen Biotech | P2 | B |
| Valproic Acid | Medical University of South Carolina | P2 | B |
| Nivolumab | Jason J. Luke, MD | P2 | B |
| Camustine | University of California, Davis | P3 | B |
| Carboplatin | DelMar Pharmaceuticals, Inc. | P3 | B |
+42 more in the Glioma cohort
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Rhenium Liposome Treatment in Glioma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/rhenium-liposome-treatment-glioma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →